The obesity market is driving pharma’s return on investment (ROI) upward, with the projected return rising to 5.9% overall in 2024, but only reaching 3.8%

I’ve been meaning to write about this paper, although it’s not exactly medicinal chemistry (!) But it is a really novel – and rather daring

A WOMAN has revealed the bizarre side effect of taking fat loss injections. Amy Kane lost 11 stone with the weight loss drug and is

What You Should Know:  – FuturHealth, a provider of personalized weight-loss solutions partners with Affirm, the payment network that empowers consumers and helps merchants drive

What You Should Know:  – The pharmaceutical research and development (R&D) sector is experiencing a significant upswing, with projected returns on investment climbing to 5.9%

A recent study published in Nature Medicine may provide valuable insights into the previously unreported benefits and risks of glucagon-like peptide-1 (GLP-1) receptor agonist use

In the UK more than 3 in every 1000 people are taking glucagon-like peptide-1 (GLP-1) agonist drugs, says Kevin McCarroll, consultant physician and geriatrician at

Related Stocks: NAS:AFRM,

With GLP-1 drugs like Ozempic all the rage, ChipMonk Baking has created a cookie it says works a bit the same way.

GLP-1s are driving traditional drug spending in the U.S. to unprecedented levels, which now outpaces specialty drug spending for the first time, according to a

Novo Nordisk said on Monday all eligible cash-paying customers in the United States can buy its weight-loss drug Wegovy at a discounted price of $499

Tirzepatide, a dual GIP/GLP-1 receptor agonist for diabetes, suppresses colorectal cancer growth by targeting glucose metabolism. It inhibits cancer cell proliferation, promotes apoptosis, and induces

Patients with diabetes or obesity receiving GLP-1 RAs are unlikely to experience an increase in the already low rates of suicide-related adverse events in clinical

It was only a matter of time until the GLP-1 receptor agonist drugs like Ozempic and Wegovy were superseded, and now it looks like we’ll

Amy Schumer is keeping people updated on her health. The 43-year-old comedian informed fans about her experience with taking an alternative weight loss drug called

Building upon its already impressive obesity drug portfolio, Novo Nordisk A/S has licensed a triple agonist of the receptors for GLP-1, GIP and glucagon from

With a FDA deadline set for March 26 to stop compounding versions of Zepbound, followed by restrictions on compounded Ozempic and Wegovy set for later

Learn how chemists have invented a new technology to solve the shortage of GLP-1 medications by improving drug delivery.

Huel Black Edition protein I’ve been loving Huel’s Ready-To-Drinks, but that’s only half of what the Black Edition collection has to offer. Maybe you’re more

Novo Nordisk is licensing rights to a United Biotechnology drug that sparks metabolic effects by binding to and activating receptors for GLP-1, GIP, and glucagon.

A company is looking for a Clinical Care Advocate to support patients by addressing inquiries and ensuring a seamless patient experience. Key Responsibilities Serve as

The candidate at the center of the deal, dubbed UBT251, is a triple agonist for glucagon-like peptide-1 (GLP-1), gastric inhibitory polypeptide (GIP) and glucagon.

Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating, because that oh-so-familiar routine of meetings, deadlines,

Novo Nordisk pays $200M upfront for China-based biotech’s triple-G obesity shot  Endpoints News Novo Signs $2 Billion Deal With United Labs for Obesity Drug  Bloomberg The United

Making America healthy again, it seems, starts with a double cheeseburger and fries. Earlier this month, Health Secretary Robert F. Kennedy Jr. visited a Steak

LONDON–(BUSINESS WIRE)–Closed Loop Medicine Ltd., a leader in AI-enabled precision medicines, today announced the expansion of its US patent portfolio. Strengthening its cardiometabolic treatment portfolio,